# A Phase 2 Study of HW211026 in Participants With Actinic Keratosis

> **NCT07513454** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** HW211026
- **DRUG:** HW211026

## Key facts

- **NCT ID:** NCT07513454
- **Lead sponsor:** Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07513454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07513454, "A Phase 2 Study of HW211026 in Participants With Actinic Keratosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07513454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*